secwatch.observer — SEC 8-K summary
======================================

Issuer:     TriSalus Life Sciences, Inc. (TLSI)
CIK:        0001826667
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001826667-25-000049
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TriSalus Q1 rev $9.2M (+42% YoY); revises 2025 guidance: 50% growth, no adj. EBITDA positive
--------------------------------------------------------------------------------

- Net sales $9.2M, up 42% YoY and 11% sequential; gross margin 84% vs 85%.
- Net loss available to common $10.4M ($0.39 diluted loss per share) vs $13.2M ($0.60) prior year.
- Adjusted EBITDA loss narrowed to $5.5M from $10.4M; cash $13.0M at Mar 31, then raised $22M via private placement.
- 2025 guidance: confirms 50% rev growth; no longer expects adj. EBITDA or cash flow positive in 2025.
- Agreement with 55% of preferred shareholders to simplify capital structure; preferred conversion by mid-July 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826667/000182666725000049/0001826667-25-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826667/000182666725000049/tlsi-20250515.htm
  HTML page:      https://secwatch.observer/filing/0001826667-25-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer